Compare Merck & Co., Inc. (MRK) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Merck & Co., Inc. trades at $148.1 (market cap $366.28B), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $58.5. The key difference: Merck & Co., Inc. pays a 2.29% dividend while SP Funds S&P 500 Sharia Industry Exclusions ETF pays none. Which is the better fit depends on your goals.
| MRK | SPUS | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $156.43 | $59.51 |
52-Week Low | $77.60 | $46.65 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
SPUS trades at $58.72, down 0.53% on the day, with technical indicators showing a neutral to slightly bullish bias. The stock exhibits a narrow trading range with key support and resistance clustered around $58-$59. Recent corporate actions include small quarterly dividends, but key fundamental valuation and profitability ratios are not publicly reported, limiting traditional analysis. No major recent news or earnings data is available to drive sentiment.
The outlook for SPUS is clouded by a lack of accessible fundamental data, presenting a challenge for valuation. The primary opportunity lies in potential undiscovered value, while the significant risk is the inability to assess the company's financial health, earnings power, or competitive position, making it a speculative holding dependent on broader market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →
